Table 1.

Examples of patients with risk factors of thrombosis who received adenoviral (Ad) vector-based SARS-CoV-2 vaccines and developed VITT and their characteristics.

Gender	Age	Vaccine type	Dose	Risk factor	Thrombosis site	Ref
–	–	ChAdOx1 nCov-19	First	Type 1 von Willebrand disease Factor V Leiden Anti-cardiolipin antibodies	Splanchnic-vein, Pulmonary, Cerebral sinus	[2]
Female	37	ChAdOx1 nCoV-19	First	Oral contraceptive pill	Cortical veins, left transverse sinus, and sigmoid left sinus	[5]
Female	42	ChAdOx1 nCoV-19	First	Contraceptive vaginal ring	Cortical veins, left transverse sinus, and sigmoid left sinus	[5]
Female	54	ChAdOx1 nCoV-19	First	Hormone-replacement therapy	Cortical veins, superior sagittal sinus, both transverse sinuses, and left sigmoid sinus	[5]
–	–	ChAdOx1 nCoV-19	First	Oral contraceptive pill	–	[2]
–	–	ChAdOx1 nCoV-19	First	Deep vein thrombosis	–	[2]
Female	<60	Ad26.COV2.S	First	Obesity Hypothyroidism Oral contraceptive pill	Cerebral venous sinus thrombosis	[67]